FULVESTRANT

Urothelial Carcinoma Bladder

Rain Oncology IncSmall moleculePhase 1/2Active

CC

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 81/ 100

Competitive context

12 Active assets in the Urothelial Carcinoma Bladder cohort.

Asset / Sponsor	Phase	Rating
Pembrolizumab Fred Hutchinson Cancer Center	Phase 3	BB
io102-io103 IO Biotech	Phase 2	B
Toripalimab Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 2	CCC
tamivarotene Nagoya University	Phase 2	CCC
9mw2821 Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 2	CCC

View all 19 →

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant

BB

Indicative ·

70 / 100

hormone receptor-positive breast cancerDormant

BB

Indicative ·

70 / 100

Progesterone Receptor PositiveDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.